<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31660997</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine.</ArticleTitle><Pagination><StartPage>122</StartPage><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-019-1233-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Conventional assays to titrate polioviruses usually test serial dilutions inoculated into replicate cell cultures to determine a 50% cytopathic endpoint, a process that is both time-consuming and laborious. Such a method is still used to measure potency of live Oral Poliovirus Vaccine during vaccine development and production and in some clinical trials. However, the conventional method is not suited to identify and titrate virus in the large numbers of fecal samples generated during clinical trials. Determining titers of each of the three Sabin strains co-existing in Oral Poliovirus Vaccine presents an additional challenge.</AbstractText><AbstractText Label="RESULTS">A new assay using quantitative multiplex polymerase chain reaction as an endpoint instead of cytopathic effect was developed to overcome these limitations. In the multiplex polymerase chain reaction-based titration assay, cell cultures were infected with serial dilutions of test samples, lysed after two-day incubation, and subjected to a quantitative multiplex one-step reverse-transcriptase polymerase chain reaction. All three serotypes of poliovirus were identified in single samples and titers calculated. The multiplex polymerase chain reaction-based titration assay was reproducible, robust and sensitive. Its lower limits of titration for three Sabin strains were 1-5 cell culture 50% infectious doses per ml. We prepared different combinations of three Sabin strains and compared titers obtained with conventional and multiplex polymerase chain reaction-based titration assays. Results of the two assays correlated well and showed similar results and sensitivity. Multiplex polymerase chain reaction-based titration assay was completed in two to 3 days instead of 10 days for the conventional assay.</AbstractText><AbstractText Label="CONCLUSIONS">The multiplex polymerase chain reaction-based titration (MPBT) is the first quantitative assay that identifies and titrates each of several different infectious viruses simultaneously in a mixture. It is suitable to identify and titrate polioviruses rapidly during the vaccine manufacturing process as a quality control test, in large clinical trials of vaccines, and for environmental surveillance of polioviruses. The MPBT assay can be automated for high-throughput implementation and applied for other viruses including those with no cytopathic effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manukyan</LastName><ForeName>Hasmik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodionova</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagorodnyaya</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Tsai-Lien</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laassri</LastName><ForeName>Majid</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0110-5504</Identifier><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. majid.laassri@fda.hhs.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008828" MajorTopicYN="N">Microbiological Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060885" MajorTopicYN="N">Multiplex Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Mucosal immunity</Keyword><Keyword MajorTopicYN="N">Multiplex titration</Keyword><Keyword MajorTopicYN="N">Poliovirus surveillance</Keyword><Keyword MajorTopicYN="N">Virus excretion</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31660997</ArticleId><ArticleId IdType="pmc">PMC6819588</ArticleId><ArticleId IdType="doi">10.1186/s12985-019-1233-6</ArticleId><ArticleId IdType="pii">10.1186/s12985-019-1233-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Polio vaccines: WHO position paper - March 2016. Weekly epidemiological record. Geneva: WHO Press; 2016. p. 145&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162(6):1291&#x2013;1297. doi: 10.1093/infdis/162.6.1291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/162.6.1291</ArticleId><ArticleId IdType="pubmed">2172403</ArticleId></ArticleIdList></Reference><Reference><Citation>This-week. Polio this week as of 18 October 2017. This Week &#x2013; GPEI - Global Polio Eradication Initiative. 2017. http://polioeradication.org/polio-today/polio-now/this-week/.</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283&#x2013;S293. doi: 10.1093/infdis/jiu295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587&#x2013;635. doi: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl 1):S380&#x2013;S389. doi: 10.1093/infdis/jiu184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu184</ArticleId><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Sixty-Ninth World Health Assembly, Provisional Agenda Item 14.5. Poliomyelitis. 2016. pp. A69&#x2013;A25.</Citation></Reference><Reference><Citation>John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014;384(9953):1505&#x2013;1512. doi: 10.1016/S0140-6736(14)60934-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60934-X</ArticleId><ArticleId IdType="pubmed">25018120</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin J, Ottosen A, Ghazieh A, Fournier-Caruana J, Ntow AK, Gonzalez AR. Managing the planned cessation of a global supply market: lessons learned from the global cessation of the trivalent oral poliovirus vaccine market. J Infect Dis. 2017;216(suppl_1):S40&#x2013;SS5. doi: 10.1093/infdis/jiw571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw571</ArticleId><ArticleId IdType="pmc">PMC5853836</ArticleId><ArticleId IdType="pubmed">28838167</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217(3):371&#x2013;380. doi: 10.1093/infdis/jix556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix556</ArticleId><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017;216(suppl_1):S176&#x2013;SS82. doi: 10.1093/infdis/jix108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix108</ArticleId><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377&#x2013;1384. doi: 10.1016/S1473-3099(16)30169-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30169-4</ArticleId><ArticleId IdType="pmc">PMC5611465</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16(3):321&#x2013;330. doi: 10.1016/S1473-3099(15)00488-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00488-0</ArticleId><ArticleId IdType="pmc">PMC9108810</ArticleId><ArticleId IdType="pubmed">26719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht P, Enterline JC, Boone EJ, Klutch MJ. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand. 1983;11(2):91&#x2013;97. doi: 10.1016/S0092-1157(83)80031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(83)80031-6</ArticleId><ArticleId IdType="pubmed">6306012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bey E, Golombick T. A comparison of three methods for titration of poliovirus vaccines. J Virol Methods. 1984;9(2):123&#x2013;130. doi: 10.1016/0166-0934(84)90004-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-0934(84)90004-1</ArticleId><ArticleId IdType="pubmed">6096387</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrath DI, Seagroatt V. The standardization of infectivity titrations of poliovaccines--a WHO collaborative study. J Biol Stand. 1985;13(2):159&#x2013;166. doi: 10.1016/S0092-1157(85)80022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(85)80022-6</ArticleId><ArticleId IdType="pubmed">3997898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bareither R, Pollard D. A review of advanced small-scale parallel bioreactor technology for accelerated process development: current state and future need. Biotechnol Prog. 2011;27(1):2&#x2013;14. doi: 10.1002/btpr.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.522</ArticleId><ArticleId IdType="pubmed">21312350</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M, Dipiazza A, Bidzhieva B, Zagorodnyaya T, Chumakov K. Quantitative one-step RT-PCR assay for rapid and sensitive identification and titration of polioviruses in clinical specimens. J Virol Methods. 2013;189(1):7&#x2013;14. doi: 10.1016/j.jviromet.2012.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.12.015</ArticleId><ArticleId IdType="pubmed">23305817</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H, Zagorodnyaya T, Ruttimann R, Manor Y, Bandyopadhyay A, Shulman L, et al. Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimens. J Virol Methods. 2018;259:74&#x2013;80. doi: 10.1016/j.jviromet.2018.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2018.06.009</ArticleId><ArticleId IdType="pubmed">29920299</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388(10040):158&#x2013;169. doi: 10.1016/S0140-6736(16)00703-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00703-0</ArticleId><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Technical Report Series No. 673 [Internet]. Geneva: WHO; 1982. Available from: http://apps.who.int/iris/bitstream/handle/10665/41534/WHO_TRS_673.pdf?sequence=1.</Citation></Reference><Reference><Citation>Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci U S A. 1952;38(8):747&#x2013;752. doi: 10.1073/pnas.38.8.747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.38.8.747</ArticleId><ArticleId IdType="pmc">PMC1063645</ArticleId><ArticleId IdType="pubmed">16589172</ArticleId></ArticleIdList></Reference><Reference><Citation>Forcic D, Kosutic-Gulija T, Santak M, Jug R, Ivancic-Jelecki J, Markusic M, et al. Comparisons of mumps virus potency estimates obtained by 50% cell culture infective dose assay and plaque assay. Vaccine. 2010;28(7):1887&#x2013;1892. doi: 10.1016/j.vaccine.2009.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.11.049</ArticleId><ArticleId IdType="pubmed">19961964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber D, Bailer SM. Determination of HSV-1 infectivity by plaque assay and a luciferase reporter cell line. Methods Mol Biol. 2013;1064:171&#x2013;181. doi: 10.1007/978-1-62703-601-6_12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-601-6_12</ArticleId><ArticleId IdType="pubmed">23996257</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes M, Camacho LA, Yamamura AM, Miranda EH, Cajaraville AC, da Silva Freire M. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals. 2012;40(6):399&#x2013;404. doi: 10.1016/j.biologicals.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2012.09.005</ArticleId><ArticleId IdType="pubmed">23034357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LA, Scott TW. Differential evolution of eastern equine encephalitis virus populations in response to host cell type. Genetics. 2001;157(4):1403&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461603</ArticleId><ArticleId IdType="pubmed">11290699</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBarre DD, Lowy RJ. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods. 2001;96(2):107&#x2013;126. doi: 10.1016/S0166-0934(01)00316-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-0934(01)00316-0</ArticleId><ArticleId IdType="pubmed">11445142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 2011;7(12):e1002390. doi: 10.1371/journal.ppat.1002390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002390</ArticleId><ArticleId IdType="pmc">PMC3228792</ArticleId><ArticleId IdType="pubmed">22144891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Bueno A, Mateu MG, Almendral JM. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J Virol. 2003;77(4):2701&#x2013;2708. doi: 10.1128/JVI.77.4.2701-2708.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.4.2701-2708.2003</ArticleId><ArticleId IdType="pmc">PMC141124</ArticleId><ArticleId IdType="pubmed">12552010</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka A, Gibbs CJ, Jr, Gajdusek DC. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch Virol. 1985;84(3&#x2013;4):197&#x2013;206. doi: 10.1007/BF01378972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01378972</ArticleId><ArticleId IdType="pubmed">2859845</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldao A, Oliveira R, Carrondo MJ, Alves PM. Error assessment in recombinant baculovirus titration: evaluation of different methods. J Virol Methods. 2009;159(1):69&#x2013;80. doi: 10.1016/j.jviromet.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.03.007</ArticleId><ArticleId IdType="pubmed">19442848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Nankya I, Abraha A, Troyer RM, Nelson KN, Rubio A, et al. Calculating HIV-1 infectious titre using a virtual TCID(50) method. Methods Mol Biol. 2009;485:27&#x2013;35. doi: 10.1007/978-1-59745-170-3_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-170-3_3</ArticleId><ArticleId IdType="pubmed">19020816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadgir SV, Hensler HR, Knowlton ER, Rinaldo CR, Rappocciolo G, Jenkins FJ. Fifty percent tissue culture infective dose assay for determining the titer of infectious human herpesvirus 8. J Clin Microbiol. 2013;51(6):1931&#x2013;1934. doi: 10.1128/JCM.00761-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00761-13</ArticleId><ArticleId IdType="pmc">PMC3716109</ArticleId><ArticleId IdType="pubmed">23554189</ArticleId></ArticleIdList></Reference><Reference><Citation>European-Pharmacopoiea. Poliomyelitis vaccine (inactivated). 7th ed. Strasbourg: EuropeanPharmacopoiea; 2011. p. 815&#x2013;7.</Citation></Reference><Reference><Citation>Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV., Jr Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand. 1989;17(2):137&#x2013;150. doi: 10.1016/0092-1157(89)90004-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-1157(89)90004-8</ArticleId><ArticleId IdType="pubmed">2541133</ArticleId></ArticleIdList></Reference><Reference><Citation>Karber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f experiment Pathol u Pharmakol. 1931;162:480&#x2013;483. doi: 10.1007/BF01863914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01863914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>